Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer Treated With Total Neoadjuvant Therapy Followed by Watch and Wait or Total Mesorectal Excision Based on Clinical Assessment of Response

NCT05674422 is registered in ClinicalTrials.gov with Grupo Espanol Multidisciplinario del Cancer Digestivo as lead sponsor.

NCT NCT05674422
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05674422 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer Treated With Total Neoadjuvant Therapy Followed by Watch and Wait or Total Mesorectal Excision Based on Clinical Assessment of Response
Lead sponsor
Grupo Espanol Multidisciplinario del Cancer Digestivo
Phase
Observational
Overall status
Active, not recruiting
Start date
May 26, 2023
Completion date
July 31, 2026
Enrollment
120 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

patients with locally advanced rectal cancer